Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: A Gynecologic Oncology Group study

Abdulhay, Gazi; DiSaia, Philip J.; Blessing, John A.; Creasman, William T.

doi:10.1016/s0002-9378(85)80151-4

Cited by 32 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic administration of IFN-alpha in ovarian cancer patients resulted in responses in less than 10% with a high frequency of dose-limiting cytokine toxicity (Abdulhay et al 1985;Niloff et al 1985). The response rate for the intraperitoneal cytokines, IFN-alpha and IFN -gamma, is comparable with the cytotoxic agents, i.e., about 30-50% (Berek et al 1985;Willemse et al 1990;Pujade-Lauraine et al 1991).…”

Section: Discussionmentioning

confidence: 99%

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

Zanten-Przybysz

Molthoff

Gebbinck

et al. 2002

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

Zanten-Przybysz

Molthoff

Gebbinck

et al. 2002

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Previous experiences using a-IFN by a systemic route have shown only a marginal activity in ovarian cancer [17]. Preclinical data have shown that IFN possesses anti proliferative effects on ovarian cancer cell growth in vitro [9,18].…”

Section: Discussionmentioning

confidence: 99%

Experience with Intraperitoneal Alpha-2a Interferon

Nicoletto

Fiorentino

Vinante³

et al. 1992

Oncology

View full text Add to dashboard Cite

Eighteen patients affected with epithelial ovarian cancer have been treated by intraperitoneal α_2a-Interferon. The usual single dosage was 54 x 10⁶ U at weekly intervals for four times (eight times in responders): 10 h-istologically confirmed complete remissions and 3 partial remissions have been obtained; the toxicity was represented by fever in the majority of the cases, by abdominal discomfort in some cases, and by a mild transitory neurological complication in 1 case. Seventeen of 18 patients were pretreated, and 11 of 18 had only cytologic and/or microscopic disease. α_2a-Interferon has proven to be very effective and moderately toxic in microscopic peritoneal disease of ovarian epithelial cancer previously treated with extensive surgery and intravenous cytotoxic chemotherapy.

show abstract

“…The adverse effects of Interferon therapy in the ovarian cancer are fatigue, leukopenia and thrombocytopenia, and more rarely nephrotoxicity and myocardial infarction (Abdulhay G et al 1985).…”

Section: Ovarian Cancer/pseudomyxoma Peritoneimentioning

confidence: 99%

Utilization of Interferon in Gynecologic and Breast Cancer

Nomelini

Mardegan

Murta

2007

Clinical medicine. Oncology

View full text Add to dashboard Cite

Abstract:The usual treatment of gynecologic cancer has been surgery, chemotherapy and radiotherapy. New therapies are being developed to improve efficacy of treatment. Interferons are inducible secretory glycoproteins that have immunomodulatory, antiviral, anti-angiogenic and anti-proliferative effects. Their potential antitumor effect has been demonstrated in many studies. Some patients obtain benefi cial effects; in other patients the treatment failure can occur. IFNs can modulate the immune response and inhibition of tumor angiogenesis. When any alteration in gene expression occurs, there is modulation of the receptors of other cytokines and enzymes that control cell function. These alterations can infl uence the differentiation, cell proliferation rate and apoptosis. The molecular mechanisms that control apoptotic cell death can be improved through cancer management using IFN in single, combination or adjuvant treatment. Malignant cells generally present defects in programmed cell death and apoptosis. Immunomodulation and angiogenesis inhibition are indirect antitumor mechanisms mediated by apoptosis. With regard to immunomodulation, IFNs can have antitumor effects through increases in cytotoxic T cells, natural killer cells and dendritic cells. Angiogenesis inhibition can result from endothelial cell apoptosis. This factor is important in inhibiting tumor genesis and forming metastases. The aim of this review is to discuss the role of Interferon in the treatment of gynecologic malignancies/breast cancer and mechanisms of action.

show abstract

Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: A Gynecologic Oncology Group study

Cited by 32 publications

References 9 publications

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

Experience with Intraperitoneal Alpha-2a Interferon

Utilization of Interferon in Gynecologic and Breast Cancer

Contact Info

Product

Resources

About